4 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
Follow Repligen Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression RG2417, Placebo - Bipolar I Depression | Phase 2 | Completed | Repligen Corporation | 180 | 2008-11-01 | 2011-01-17 |
| Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression Uridine - Bipolar Depression | Phase 2 | Completed | Repligen Corporation | 80 | 2006-03-01 | 2007-11-09 |
| Effects of RG1068 (Secretin) on Information Processing in Schizophrenia Subcutaneous Secretin - Schizophrenia | Phase 2 | Completed | Indiana University | 30 | 2005-11-01 | 2017-03-03 |
| Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder RG1068 (Synthetic Human Secretin) - Obsessive Compulsive Disorder (OCD) | Phase 2 | Completed | Indiana University | 12 | 2005-02-01 | 2024-02-23 |
Bipolar Disorder (2) · Depression (1) · Obsessive-Compulsive Disorder (1) · Schizophrenia (1)
Uridine (2) · Secretin (1) · Sugars (1)
United States (4)
Anantha Shekhar, MD, PhD (2) · David Jacoby, MD, PhD (1) · Gary Sachs, MD (1)